Here are the 10-Q quarterly reports from Ainos, Inc. Warrants (AIMDW) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow AIMDW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AIMDW filings page.
Ainos, Inc., a Texas-based developer of AI-enabled olfactory sensing (AI Nose) and immune therapeutics, reported very limited revenue while remaining deeply loss-making for the quarter and six months ended June 30, 2026. Revenue was $152 in Q2 2026 and $313 in H1 2026, down sharply from $4,663 and $110,870 a year earlier as the company reduced VELDONA pet supplement sales and shifted AI Nose efforts toward industrial rather than healthcare-adjacent applications.
Net loss totaled $4.6M for Q2 2026 and $7.1M for H1 2026, compared with $4.1M and $7.4M in the prior-year periods, as operating expenses eased to $6.7M from $7.0M. Basic and diluted net loss per share was $0.62 for Q2 and $1.05 for H1 2026. Cash and cash equivalents increased to $1.4M at June 30, 2026 from $0.4M at December 31, 2025, mainly driven by a $2.8M short-term loan from ASE Test, Inc. and $0.6M of net equity raised under an at-the-market offering.
Total assets were $19.6M, while stockholders’ equity fell to $3.3M from $7.6M. Current liabilities rose to $16.3M, including $11.0M of convertible notes now classified as current and the new loan payable. With an accumulated deficit of $74.6M, ongoing operating losses, and dependence on external financing, the company states that substantial doubt exists about its ability to continue as a going concern. Operationally, Ainos continued to advance AI Nose deployments and validation in semiconductor manufacturing, robotics, industrial infrastructure, and healthcare environments, including work tied to an initial $2.1M backend semiconductor commercial arrangement, while progressing its VELDONA interferon programs selectively and pursuing partnering and out-licensing opportunities.
Ainos, Inc. reported Q1 2026 results showing minimal revenue and continued losses while shoring up liquidity with new financing. Revenue was just $161, down sharply from $106,207 a year earlier as the company shifted AI Nose activity from healthcare-adjacent uses toward earlier-stage industrial deployments.
The net loss narrowed to $2,459,800 from $3,286,022, helped by a 30% reduction in operating expenses, especially lower share-based compensation and SG&A. Cash and cash equivalents rose to $2,841,422 from $417,353 at year-end, driven by a new related-party loan of about $2,812,940 and $601,600 of net proceeds from an at-the-market equity program.
Total liabilities increased to $16,389,637, including $11,000,000 of related-party convertible notes, while stockholders’ equity declined to $5,691,946. Management states that recurring losses, an accumulated deficit of $69,980,128, and dependence on future financings create “substantial doubt” about the company’s ability to continue as a going concern.